New program aims to ease burden on schizophrenia caregivers
NCT ID NCT07173192
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests an individual empowerment program for primary caregivers of people with schizophrenia. The program includes six training sessions to help caregivers cope better. Researchers will measure whether it reduces care burden and improves psychological well-being and self-efficacy compared to standard discharge education. The study involves 66 caregivers in Turkey.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- individual empowerment program (behavioral intervention)
- What this could lead to
- If it works, this program could provide a simple, low-cost way to improve the mental health and coping skills of people caring for loved ones with schizophrenia.
- What could go wrong
- This is a small, early-stage study with only 66 participants, so results may not apply to all caregivers. The program is behavioral, so benefits depend on individual engagement and may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 66 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Feb 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Being the primary caregiver of a patient diagnosed with schizophrenia and other psychotic disorders Volunteering to participate in the study Being 18 years of age or older Being literate Not having a psychiatric illness (diagnosis) Not having a serious mental or physical disorder that prevents communication Exclusion Criteria: Providing care to patients with severe organic brain syndrome such as alcohol or substance dependence, intellectual disability, dementia, or delirium, or with a previous or current general medical condition that could impair cognitive function Withdrawal from the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Istanbul Arel University
Istanbul, Cevizlibağ, 34010, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia